JP2014528776A - 薬剤送達システムおよびその製造方法 - Google Patents
薬剤送達システムおよびその製造方法 Download PDFInfo
- Publication number
- JP2014528776A JP2014528776A JP2014527262A JP2014527262A JP2014528776A JP 2014528776 A JP2014528776 A JP 2014528776A JP 2014527262 A JP2014527262 A JP 2014527262A JP 2014527262 A JP2014527262 A JP 2014527262A JP 2014528776 A JP2014528776 A JP 2014528776A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- barrier layer
- medical device
- gcib
- neutral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012377 drug delivery Methods 0.000 title description 21
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 347
- 229940079593 drug Drugs 0.000 claims abstract description 339
- 230000007935 neutral effect Effects 0.000 claims abstract description 197
- 230000004888 barrier function Effects 0.000 claims abstract description 129
- 238000000034 method Methods 0.000 claims abstract description 80
- 238000010884 ion-beam technique Methods 0.000 claims abstract description 38
- 238000000576 coating method Methods 0.000 claims abstract description 29
- 229940088679 drug related substance Drugs 0.000 claims abstract description 9
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 6
- 239000010410 layer Substances 0.000 claims description 169
- 239000000463 material Substances 0.000 claims description 72
- 239000011247 coating layer Substances 0.000 claims description 35
- 238000010828 elution Methods 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 238000000151 deposition Methods 0.000 claims description 26
- 239000011248 coating agent Substances 0.000 claims description 24
- 238000004090 dissolution Methods 0.000 claims description 24
- 239000012530 fluid Substances 0.000 claims description 24
- 238000009792 diffusion process Methods 0.000 claims description 23
- 238000009499 grossing Methods 0.000 claims description 17
- 230000002792 vascular Effects 0.000 claims description 13
- 230000001678 irradiating effect Effects 0.000 claims description 9
- 238000003763 carbonization Methods 0.000 claims description 8
- 238000004132 cross linking Methods 0.000 claims description 8
- 238000000280 densification Methods 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 6
- 230000000975 bioactive effect Effects 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 230000002123 temporal effect Effects 0.000 claims description 2
- 238000002715 modification method Methods 0.000 claims 1
- 239000007789 gas Substances 0.000 description 195
- 150000002500 ions Chemical class 0.000 description 137
- 238000012545 processing Methods 0.000 description 67
- 239000000178 monomer Substances 0.000 description 66
- 238000011282 treatment Methods 0.000 description 50
- 230000001133 acceleration Effects 0.000 description 47
- 229920000642 polymer Polymers 0.000 description 47
- 230000008569 process Effects 0.000 description 30
- 238000004980 dosimetry Methods 0.000 description 27
- 239000000758 substrate Substances 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- 238000011068 loading method Methods 0.000 description 24
- 238000005259 measurement Methods 0.000 description 24
- 230000004907 flux Effects 0.000 description 18
- 230000007246 mechanism Effects 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 230000008901 benefit Effects 0.000 description 15
- 210000001124 body fluid Anatomy 0.000 description 14
- 239000010408 film Substances 0.000 description 14
- 230000001276 controlling effect Effects 0.000 description 13
- 230000008021 deposition Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000010839 body fluid Substances 0.000 description 11
- 238000002513 implantation Methods 0.000 description 11
- 229920001577 copolymer Polymers 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229920002959 polymer blend Polymers 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000002344 surface layer Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 6
- 239000004020 conductor Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000010304 firing Methods 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 208000037803 restenosis Diseases 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 238000007740 vapor deposition Methods 0.000 description 6
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 5
- 239000010952 cobalt-chrome Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000007598 dipping method Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000011261 inert gas Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 239000004065 semiconductor Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000011277 treatment modality Methods 0.000 description 5
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004924 electrostatic deposition Methods 0.000 description 4
- 238000005530 etching Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000004544 sputter deposition Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 239000003989 dielectric material Substances 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 239000012777 electrically insulating material Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 238000001771 vacuum deposition Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000000089 atomic force micrograph Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000003746 surface roughness Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 238000005280 amorphization Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001312 dry etching Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 239000000615 nonconductor Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000012855 volatile organic compound Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
- A61L2300/61—Coatings having two or more layers containing two or more active agents in different layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Prostheses (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
本発明の上述の目的およびさらにその他の目的と利点は、以下に述べる発明によって達成される。本発明は、表面(外科的植込み物を対象とした医療装置の表面を含む)に付着される材料(薬剤を含む)の中性ビーム処理を使用して、(たとえば溶出、蒸着、または昇華によって)材料が表面から放出される速度を変更し遅延する、あるいは向上させることに関する。植込み型薬剤コーティング医療装置の場合、放出機構は通常溶出による。
以下の説明では、簡潔化のため、上述の図の要素符号が、後述の図で説明なく使用される場合がある。同様に、上述の図に関して説明した要素が、後述の図で要素符号または追加の説明なく使用される場合がある。このような場合、類似の符号を付した要素は類似の要素であり、上述の特徴および機能を有し、本図面に示される要素符号を付していない要素の説明は、上述の図面に示される類似の要素と同一の機能を有する類似の要素を指す。
Claims (19)
- 一つまたはそれ以上の薬剤を送達する表面を有する医療装置であって、前記装置の前記表面上の一つまたはそれ以上の薬剤コーティング層を備え、前記薬剤コーティング層のうち少なくとも一つが少なくとも一つのバリア層を有して前記少なくとも一つのバリア層全体にわたる材料の流速を制御し、前記少なくとも一つのバリア層が中性ビーム照射によって改質される薬剤から成ることを特徴とする医療装置。
- 前記少なくとも一つのバリア層が、
薬剤の放出速度を制御するか、
薬剤の溶出速度を制御するか、または
流体の前記一つまたはそれ以上の薬剤コーティング層のうち少なくとも一つへの内方拡散速度を制御することを特徴とする請求項1の医療装置。 - 前記一つまたはそれ以上の薬剤コーティング層の少なくとも一つの薬剤コーティング層が、第一の量の第一の薬剤を含有しており、改質された第一の薬剤を備える第一のバリア層によって前記第一の薬剤が覆われており、第二の量の第二の薬剤によって前記第一のバリア層が覆われており、改質された第二の薬剤を備える第二のバリア層によって前記第二の薬剤が覆われることを特徴とする請求項1の医療装置。
- 前記第一の薬剤と前記第二の薬剤とが、同一の薬剤または異なる薬剤であり、
前記第一のバリア層と前記第二のバリア層とが、前記第一の薬剤と前記第二の薬剤の時間的な放出特性を制御するように構成されていることを特徴とする請求項3の医療装置。 - 前記制御流速が、
薬剤溶出速度、
薬剤放出速度、または
流体拡散速度であることを特徴とする請求項1の医療装置。 - 前記医療装置が、
血管ステント、
冠状動脈ステント、
人工関節補綴物、
人工関節補綴物部品、または
冠状動脈ペースメーカのいずれかであることを特徴とする請求項1の医療装置。 - 変質した薬剤を備える前記少なくとも一つのバリア層が、
架橋薬剤分子、
緻密化薬剤、
炭化有機薬剤物質、
ポリマー化薬剤、または
変性薬剤、および
それらの組み合わせから成る群から選択されることを特徴とする請求項1の医療装置。 - 前記少なくとも一つのバリア層が生物活性物質を含んでいることを特徴とする請求項1の医療装置。
- 医療装置の表面改質方法であって、
a.前記医療装置の表面の少なくとも一部に第一の薬剤コーティング層を蒸着するステップと、
b.前記第一の薬剤コーティング層に一つまたはそれ以上の追加薬剤コーティング層を任意で蒸着して複数の薬剤コーティング層を形成するステップと、
c.加速中性ビームを形成するステップと、
d.前記第一の薬剤コーティング層または任意の追加薬剤コーティング層のうち少なくとも一つの第一の露出表面に前記中性ビームを照射して、前記第一の露出表面にバリア層を形成するステップと、
を備えることを特徴とする方法。 - 前記蒸着するステップaの前に、
第二のビームを形成するステップと、
前記医療装置の表面の少なくとも一部に前記第二のビームを第二に照射するステップと、
前記医療装置の表面の前記少なくとも一部を清掃するステップと、
前記医療装置の表面の前記少なくとも一部を平滑化するステップと、
前記医療装置の表面の前記少なくとも一部の鋭利なまたはギザギザの縁部を除去するステップと、
をさらに備えることを特徴とする請求項9の方法。 - 前記照射するステップdが、
前記薬剤の分子の架橋、
前記薬剤の緻密化、
前記薬剤の炭化、
前記薬剤のポリマー化、または
前記薬剤の変性、
によって前記露出表面で前記薬剤を改質することによって前記バリア層を形成することを特徴とする請求項9の方法。 - 前記バリア層が流体の前記薬剤コーティングへの内方拡散速度を制御することを特徴とする請求項9の方法。
- 前記バリア層が薬剤の前記薬剤コーティングからの外方溶出速度を制御することを特徴とする請求項9の方法。
- 第三のビームを形成するステップと、前記第一の薬剤コーティング層または任意の追加薬剤コーティング層のうち少なくとも一つの第二の露出表面に前記第三のビームを照射して、前記第二の露出表面に第二のバリア層を形成するステップと、をさらに備えることを特徴とする請求項9の方法。
- 前記第三のビームが中性ビームであることを特徴とする請求項14の方法。
- 前記第三のビームがガスクラスタイオンビームであることを特徴とする請求項14の方法。
- 前記第一のバリア層と前記第二のバリア層とが、2つの薬剤コーティング層の溶出速度を異なって制御するために異なる特性を有していることを特徴とする請求項14の方法。
- 前記中性ビームが加速ガスクラスタイオンビームから得られることを特徴とする請求項9の方法。
- 第一の薬剤コーティング層と追加薬剤コーティング層とが異なる薬剤物質を含んでいることを特徴とする請求項9の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161526186P | 2011-08-22 | 2011-08-22 | |
US61/526,186 | 2011-08-22 | ||
PCT/US2012/051868 WO2013028761A1 (en) | 2011-08-22 | 2012-08-22 | Drug delivery system and method of manufacturing thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014088011A Division JP6211986B2 (ja) | 2011-08-22 | 2014-04-22 | 薬剤送達システムおよびその製造方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014528776A true JP2014528776A (ja) | 2014-10-30 |
JP2014528776A5 JP2014528776A5 (ja) | 2015-08-20 |
JP6189297B2 JP6189297B2 (ja) | 2017-08-30 |
Family
ID=47746831
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014527262A Expired - Fee Related JP6189297B2 (ja) | 2011-08-22 | 2012-08-22 | 薬剤送達システムおよびその製造方法 |
JP2014088011A Expired - Fee Related JP6211986B2 (ja) | 2011-08-22 | 2014-04-22 | 薬剤送達システムおよびその製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014088011A Expired - Fee Related JP6211986B2 (ja) | 2011-08-22 | 2014-04-22 | 薬剤送達システムおよびその製造方法 |
Country Status (8)
Country | Link |
---|---|
US (3) | US10342900B2 (ja) |
EP (1) | EP2747802B1 (ja) |
JP (2) | JP6189297B2 (ja) |
AU (1) | AU2012298912B2 (ja) |
CA (1) | CA2845762C (ja) |
IL (2) | IL231068A0 (ja) |
RU (1) | RU2014110963A (ja) |
WO (1) | WO2013028761A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014198247A (ja) * | 2011-08-22 | 2014-10-23 | エクソジェネシス コーポレーション | 薬剤送達システムおよびその製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103180030B (zh) | 2010-08-23 | 2017-04-12 | 艾克索乔纳斯公司 | 基于气体团簇离子束技术的中性射束处理方法和设备 |
US9540725B2 (en) * | 2014-05-14 | 2017-01-10 | Tel Epion Inc. | Method and apparatus for beam deflection in a gas cluster ion beam system |
US20160175084A1 (en) * | 2014-12-19 | 2016-06-23 | Volcano Corporation | Biodegradable filter and support frame |
KR102347960B1 (ko) | 2015-02-03 | 2022-01-05 | 삼성전자주식회사 | 도전체 및 그 제조 방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005031838A1 (ja) * | 2003-09-30 | 2005-04-07 | Japan Aviation Electronics Industry Limited | 固体表面の平坦化方法及びその装置 |
US7638156B1 (en) * | 2005-12-19 | 2009-12-29 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for selectively coating a medical article |
WO2010017456A2 (en) * | 2008-08-07 | 2010-02-11 | Exogenesis Corporation | Drug delivery system and method of munufacturing thereof |
US20100227523A1 (en) * | 2007-09-14 | 2010-09-09 | Exogenesis Corporation | Methods for improving the bioactivity characteristics of a surface and objects with surfaces improved thereby |
JP2014525813A (ja) * | 2011-08-19 | 2014-10-02 | エクソジェネシス コーポレーション | 薬剤送達システムおよびその製造方法 |
JP2014198247A (ja) * | 2011-08-22 | 2014-10-23 | エクソジェネシス コーポレーション | 薬剤送達システムおよびその製造方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3679897A (en) | 1969-08-28 | 1972-07-25 | Trw Inc | Laser bombardment of microparticle beam for producing atomic particles in the form of a beam or an expanding cloud |
JPS60124931A (ja) | 1983-12-12 | 1985-07-04 | Mitsubishi Electric Corp | 薄膜蒸着装置 |
US4935623A (en) * | 1989-06-08 | 1990-06-19 | Hughes Aircraft Company | Production of energetic atom beams |
JPH04120732A (ja) * | 1990-09-12 | 1992-04-21 | Hitachi Ltd | 固体素子及びその製造方法 |
SE511719C2 (sv) | 1997-07-04 | 1999-11-15 | Ericsson Telefon Ab L M | Begravd heterostrukturlaser med ströminneslutande skikt |
GB9714576D0 (en) * | 1997-07-10 | 1997-09-17 | Applied Materials Inc | Method and apparatus for neutralising space charge in an ion beam |
DE19934173A1 (de) | 1999-07-21 | 2001-01-25 | Max Planck Gesellschaft | Verfahren und Vorrichtung zur Clusterfragmentation |
US6416820B1 (en) | 1999-11-19 | 2002-07-09 | Epion Corporation | Method for forming carbonaceous hard film |
DE60041149D1 (de) * | 1999-12-06 | 2009-01-29 | Tel Epion Inc | Gerät zum glätten von substraten mittels gas-cluster-ionenstrahlung |
WO2001070378A1 (en) | 2000-03-20 | 2001-09-27 | Epion Corporation | Cluster size measurement instrument and method for cluster ion beam diagnostic |
AU2001273276A1 (en) | 2000-07-10 | 2002-01-21 | Epion Corporation | Improving effectiveness of medical stents by gcib |
WO2002004696A1 (en) | 2000-07-10 | 2002-01-17 | Epion Corporation | Improving effectiveness of artificial hip by gcib |
EP1393601B1 (en) * | 2001-05-11 | 2010-09-29 | Exogenesis Corporation | Method for improving the effectiveness of medical devices by adhering drugs to the surface thereof |
US7923055B2 (en) | 2001-05-11 | 2011-04-12 | Exogenesis Corporation | Method of manufacturing a drug delivery system |
US7666462B2 (en) * | 2001-05-11 | 2010-02-23 | Exogenesis Corporation | Method of controlling a drug release rate |
US20030021908A1 (en) | 2001-07-27 | 2003-01-30 | Nickel Janice H. | Gas cluster ion beam process for smoothing MRAM cells |
US7771420B2 (en) | 2004-03-05 | 2010-08-10 | Medelec-Minimeca S.A. | Saline-enhanced catheter for radiofrequency tumor ablation |
US7405394B2 (en) | 2004-08-24 | 2008-07-29 | Hitachi, Ltd. | Gas cluster-ion irradiation apparatus |
EP1807859A2 (en) | 2004-10-25 | 2007-07-18 | TEL Epion Inc. | Ionizer and method for gas-cluster ion-beam formation |
JP2006299316A (ja) * | 2005-04-18 | 2006-11-02 | National Institute Of Advanced Industrial & Technology | 中性粒子ビームの口径拡大方法及び口径拡大装置 |
EP1813292A1 (en) * | 2006-01-25 | 2007-08-01 | Inion Oy | Surgical implant and manufacturing method |
US20080169416A1 (en) | 2007-01-17 | 2008-07-17 | Pulsed Instruments, Inc. | Apparatus and method for analysing molecules |
US9144627B2 (en) | 2007-09-14 | 2015-09-29 | Exogenesis Corporation | Methods for improving the bioactivity characteristics of a surface and objects with surfaces improved thereby |
BRPI0722224A2 (pt) | 2007-11-27 | 2014-06-03 | Noveko Trading 2008 Llc | Fibra imitando planta natural, método de preparação da mesma e pano produzido dessa fibra |
US7825389B2 (en) | 2007-12-04 | 2010-11-02 | Tel Epion Inc. | Method and apparatus for controlling a gas cluster ion beam formed from a gas mixture |
WO2009158610A2 (en) | 2008-06-26 | 2009-12-30 | Exogenesis Corporation | Method and system for sterilizing objects by the application of gas-cluster ion-beam technology |
US8217372B2 (en) * | 2009-06-30 | 2012-07-10 | Exogenesis Corporation | Gas-cluster-jet generator and gas-cluster ion-beam apparatus utilizing an improved gas-cluster-jet generator |
CN103180030B (zh) | 2010-08-23 | 2017-04-12 | 艾克索乔纳斯公司 | 基于气体团簇离子束技术的中性射束处理方法和设备 |
US9799488B2 (en) * | 2010-08-23 | 2017-10-24 | Exogenesis Corporation | Method and apparatus for neutral beam processing based on gas cluster ion beam technology |
WO2012103229A1 (en) * | 2011-01-25 | 2012-08-02 | Exogenesis Corporation | Method and system for sterilizing objects by the application of beam technology |
US9114195B2 (en) * | 2011-08-22 | 2015-08-25 | Exogenesis Corporation | Method for modifying the wettability and other biocompatibility characteristics of a surface of a biological material by the application of beam technology and biological materials made thereby |
-
2012
- 2012-08-22 EP EP12826468.6A patent/EP2747802B1/en active Active
- 2012-08-22 US US13/591,837 patent/US10342900B2/en active Active
- 2012-08-22 WO PCT/US2012/051868 patent/WO2013028761A1/en active Application Filing
- 2012-08-22 JP JP2014527262A patent/JP6189297B2/ja not_active Expired - Fee Related
- 2012-08-22 US US14/238,868 patent/US20150125510A1/en not_active Abandoned
- 2012-08-22 RU RU2014110963/15A patent/RU2014110963A/ru unknown
- 2012-08-22 AU AU2012298912A patent/AU2012298912B2/en not_active Ceased
- 2012-08-22 CA CA2845762A patent/CA2845762C/en active Active
-
2014
- 2014-02-20 IL IL231068A patent/IL231068A0/en unknown
- 2014-04-22 JP JP2014088011A patent/JP6211986B2/ja not_active Expired - Fee Related
-
2017
- 2017-08-28 IL IL254182A patent/IL254182B/en active IP Right Grant
-
2019
- 2019-07-03 US US16/502,696 patent/US20190336657A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005031838A1 (ja) * | 2003-09-30 | 2005-04-07 | Japan Aviation Electronics Industry Limited | 固体表面の平坦化方法及びその装置 |
US7638156B1 (en) * | 2005-12-19 | 2009-12-29 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for selectively coating a medical article |
US20100227523A1 (en) * | 2007-09-14 | 2010-09-09 | Exogenesis Corporation | Methods for improving the bioactivity characteristics of a surface and objects with surfaces improved thereby |
WO2010017456A2 (en) * | 2008-08-07 | 2010-02-11 | Exogenesis Corporation | Drug delivery system and method of munufacturing thereof |
US20100036482A1 (en) * | 2008-08-07 | 2010-02-11 | Exogenesis Corporation | Drug delivery system and method of manufacturing thereof |
JP2014525813A (ja) * | 2011-08-19 | 2014-10-02 | エクソジェネシス コーポレーション | 薬剤送達システムおよびその製造方法 |
JP2014198247A (ja) * | 2011-08-22 | 2014-10-23 | エクソジェネシス コーポレーション | 薬剤送達システムおよびその製造方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014198247A (ja) * | 2011-08-22 | 2014-10-23 | エクソジェネシス コーポレーション | 薬剤送達システムおよびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6189297B2 (ja) | 2017-08-30 |
JP6211986B2 (ja) | 2017-10-11 |
IL254182B (en) | 2020-08-31 |
EP2747802B1 (en) | 2022-01-12 |
JP2014198247A (ja) | 2014-10-23 |
EP2747802A1 (en) | 2014-07-02 |
WO2013028761A1 (en) | 2013-02-28 |
CA2845762A1 (en) | 2013-10-28 |
IL231068A0 (en) | 2014-03-31 |
IL254182A0 (en) | 2017-10-31 |
CA2845762C (en) | 2019-01-08 |
EP2747802A4 (en) | 2015-05-27 |
AU2012298912A1 (en) | 2014-03-06 |
RU2014110963A (ru) | 2015-09-27 |
US20130218264A1 (en) | 2013-08-22 |
US20190336657A1 (en) | 2019-11-07 |
AU2012298912B2 (en) | 2016-07-07 |
US10342900B2 (en) | 2019-07-09 |
US20150125510A1 (en) | 2015-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6388975B2 (ja) | 薬剤送達システムおよびその製造方法 | |
JP4617060B2 (ja) | 表面に薬剤を固着させて医療具の効果を高めるための方法とシステム | |
JP5448458B2 (ja) | 薬剤送達システムおよびそのシステムを製造する方法 | |
JP6211986B2 (ja) | 薬剤送達システムおよびその製造方法 | |
JP2011530347A (ja) | 薬物送達システムおよびその薬物送達システムの製造方法 | |
JP2011501984A (ja) | 医療デバイスの表面を治療剤でコーティングするための方法およびシステム、ならびにそれによって作製された薬剤溶離医療デバイス | |
JP6085604B2 (ja) | 骨インプラント用医療装置およびその製造方法 | |
US20180211813A1 (en) | Drug delivery system and method of manufacturing thereof | |
JP6185469B2 (ja) | 薬剤送達システムおよびその製造方法 | |
US10556042B2 (en) | Drug delivery system and method of manufacturing thereof | |
US20190171098A1 (en) | Drug delivery system and method of manufacturing thereof | |
US20180090295A1 (en) | Drug delivery system and method of manufacturing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150702 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160426 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160725 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160923 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170330 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170623 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170711 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170802 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6189297 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |